StockData
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. (MTNB) stock

MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)

Close on Nov 18, 2026Market cap $13.37MP/E –Yield –

Matinas BioPharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Matinas BioPharma's revenue for the twelve months ending Dec 31, 2023 was $1.10M, down 65.6% year over year. For fiscal 2023 it was $1.10M, down 65.6% from the year before. The highest annual figure on record is $3.19M in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2023Dec 31, 2023$1.10M-65.6%
FY2022Dec 31, 2022$3.19M+9560.6%
FY2021Dec 31, 2021$33.00K-79.2%
FY2020Dec 31, 2020$158.33K+76.3%
FY2019Dec 31, 2019$89.81K-25.0%
FY2018Dec 31, 2018$119.75K-20.0%
FY2017Dec 31, 2017$149.69K–
FY2016Dec 31, 2016$0-100.0%
FY2015Dec 31, 2015$194.49K–
FY2014Dec 31, 2014$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$0-100.0%
Q3 FY2023Sep 30, 2023$0-100.0%
Q2 FY2023Jun 30, 2023$0-100.0%
Q1 FY2023Mar 31, 2023$1.10M–
Q4 FY2022Dec 31, 2022$1.06M–
Q3 FY2022Sep 30, 2022$1.06M–
Q2 FY2022Jun 30, 2022$1.06M+3089.0%
Q4 FY2021Dec 31, 2021$0-100.0%
Q3 FY2021Sep 30, 2021$0-100.0%
Q2 FY2021Jun 30, 2021$0–
Q1 FY2021Mar 31, 2021$33.33K–
Q4 FY2020Dec 31, 2020$62.50K-30.4%
Q3 FY2020Sep 30, 2020$95.83K–
Q4 FY2019Dec 31, 2019$0–
Q3 FY2019Sep 30, 2019$0-100.0%
Q2 FY2019Jun 30, 2019$89.81K+200.0%
Q4 FY2018Dec 31, 2018$0-100.0%
Q3 FY2018Sep 30, 2018$0-100.0%
Q2 FY2018Jun 30, 2018$89.81K+100.0%
Q1 FY2018Mar 31, 2018$29.94K+100.0%
Q4 FY2017Dec 31, 2017$44.91K–
Q3 FY2017Sep 30, 2017$44.91K–
Q2 FY2017Jun 30, 2017$44.91K–
Q1 FY2017Mar 31, 2017$14.97K–
Q4 FY2016Dec 31, 2016$0–
Q3 FY2016Sep 30, 2016$0–

More Matinas BioPharma figures

See a number that looks wrong?